drugset
drugset / Trial / NCT00351975

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

NCT00351975 ↗

Phase 1 Completed 56 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving belinostat together with azacitidine may kill more cancer cells.

Timeline

Start
2006-06
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Belinostat Small molecule — Intravenous
Background Azacitidine Other / unclassified — Subcutaneous

Indications

acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia with t(9;11)(p22;q23) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute promyelocytic leukemia adult acute lymphoblastic leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative chronic myelomonocytic leukemia leukemia, myeloid, accelerated-phase myelodysplastic syndrome myeloproliferative neoplasm, unclassifiable primary myelofibrosis